Quarterly ResultJul 16, 2026, 04:14 PM
DBV Technologies Q2 Net Loss $(50.4)M; Cash $174.9M
AI Summary
DBV Technologies reported a net loss of $(50.4) million for the second quarter of 2026, an increase from $(41.9) million in the prior year, with six-month net loss reaching $(98.0) million. Operating expenses significantly increased, particularly in sales and marketing, as the company prepares for the potential launch of VIASKIN Peanut. Cash and cash equivalents stood at $174.9 million as of June 30, 2026, after receiving $94.7 million from warrant exercises in January. The company also secured manufacturing and commercialization agreements and expects to submit its BLA for VIASKIN Peanut in Q3 2026.
Key Highlights
- Net loss for Q2 2026 was $(50.4) million, up from $(41.9) million in Q2 2025.
- Six-month net loss increased to $(98.0) million from $(69.0) million year-over-year.
- Cash and cash equivalents totaled $174.9 million as of June 30, 2026.
- Net cash used in operating activities for six months was $(101.7) million.
- Received $94.7 million from warrant exercises in January 2026.
- Entered manufacturing agreement with Fareva La Vallée for VIASKIN Peanut source material.
- Signed letter of intent with Fareva Amboise for commercial-scale manufacturing.
- Partnered with Integrated Commercialization Solutions for US commercialization support.
- Anticipates BLA submission for VIASKIN Peanut to FDA in Q3 2026.
Price Impact
More from DBVT